Immunoassay Detects Syphilis and Assists Treatment Monitoring

A new syphilis immunoassay assay enables detection of total antibodies to Treponema pallidum subspecies pallidum (detection of IgG & IgM antibodies against TpN15, TpN17 & TpN47).

Launched by Roche (Basel, Switzerland) and dubbed the Elecsys Syphilis assay, it complements the Mediace Rapid Plasma Reagin (RPR) and T. pallidum Latex Agglutination (TPLA) Roche assays. The Immunoassay is a diagnostic test to help detect patients infected with syphilis in routine clinical practice and to make sure donated blood is not infected with syphilis. The assay demonstrates 100% sensitivity and 99.88% specificity with perfect discrimination of results, eliminating the need for a grey zone, and delivering confidence in all stages of treponemal infection.

For over 25 years Roche has invested in the research and development of serology analyzers and assays so that, today, it offers one of the most comprehensive infectious diseases assay portfolios available on a single automated platform. With the new Elecsys Syphilis assay, the Roche Diagnostics division strengthens its position in the serology market and expands its immunoassay portfolio in infectious disease. Designed for the emerging needs of clinical laboratories for reliable and efficient detection of this disease, the test enhances Roche’s solutions portfolio in serology testing––the testing of antibodies formed as a response to an infection––and complements the most comprehensive offering for blood safety available on the market today.

Related Links:
Roche